Reports Q1 revenue $0 vs. $51,000 last year. “We continue to execute on our strategy and plans and are pleased to have achieved the first milestones set for the year. First and foremost, priorities are the continued execution of the EVX-01 phase 2 trial towards readout of two-year data and bringing the collaboration on EVX-B2 and EVX-B3 with MSD to option exercise. Each of these events are significant potential value catalysts in the second half of the year. Further, we remain focused advancing our ongoing business development discussions in combination with creation of new partnering opportunities via continued enhancement of our AI-Immunology platform,” says Christian Kanstrup, CEO of Evaxion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion A/S to Announce Q1 2025 Financial Results and Business Update
- Evaxion Begins Extension of Phase 2 Trial for AI-Designed Cancer Vaccine
- Evaxion Biotech doses first patient in extension of phase 2 trial on EVX-01
- Evaxion Biotech A/S Announces Key Resolutions from April 2025 AGM
- Evaxion Biotech Updates Warrant Terms and Subscription Prices